ATE458057T1 - Varianten der faktor-vii- oder -viia-gla-domäne - Google Patents
Varianten der faktor-vii- oder -viia-gla-domäneInfo
- Publication number
- ATE458057T1 ATE458057T1 AT04738925T AT04738925T ATE458057T1 AT E458057 T1 ATE458057 T1 AT E458057T1 AT 04738925 T AT04738925 T AT 04738925T AT 04738925 T AT04738925 T AT 04738925T AT E458057 T1 ATE458057 T1 AT E458057T1
- Authority
- AT
- Austria
- Prior art keywords
- variants
- factor vii
- gla domain
- human factor
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47978003P | 2003-06-19 | 2003-06-19 | |
DKPA200400930 | 2004-06-15 | ||
PCT/DK2004/000428 WO2004111242A1 (en) | 2003-06-19 | 2004-06-18 | FACTOR VII OR VIIa GLA DOMAIN VARIANTS |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE458057T1 true ATE458057T1 (de) | 2010-03-15 |
Family
ID=33553697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04738925T ATE458057T1 (de) | 2003-06-19 | 2004-06-18 | Varianten der faktor-vii- oder -viia-gla-domäne |
Country Status (24)
Country | Link |
---|---|
US (5) | US20050164932A1 (de) |
EP (1) | EP1644504B8 (de) |
JP (2) | JP4915918B2 (de) |
KR (1) | KR101191779B1 (de) |
CN (1) | CN1839203B (de) |
AT (1) | ATE458057T1 (de) |
AU (2) | AU2004247799B2 (de) |
BR (1) | BRPI0411650A (de) |
CA (1) | CA2529828C (de) |
CY (1) | CY1109984T1 (de) |
DE (1) | DE602004025576D1 (de) |
DK (1) | DK1644504T3 (de) |
ES (1) | ES2338425T3 (de) |
HK (1) | HK1095357A1 (de) |
HR (1) | HRP20100264T1 (de) |
IL (1) | IL172364A (de) |
MX (1) | MXPA05013769A (de) |
NZ (2) | NZ573412A (de) |
PL (1) | PL1644504T3 (de) |
PT (1) | PT1644504E (de) |
RU (1) | RU2373282C2 (de) |
SI (1) | SI1644504T1 (de) |
WO (1) | WO2004111242A1 (de) |
ZA (1) | ZA200600539B (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003521930A (ja) | 2000-02-11 | 2003-07-22 | マキシゲン・エイピーエス | 第VII因子または第VIIa因子様分子 |
AU2003221469A1 (en) * | 2002-04-30 | 2003-11-17 | Bayer Healthcare Llc | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
JP4847856B2 (ja) | 2003-03-20 | 2011-12-28 | バイエル ヘルスケア エルエルシー | FVIIおよびFVIIaの変種 |
PT1644504E (pt) | 2003-06-19 | 2010-03-22 | Bayer Healthcare Llc | Variantes do domínio gla dos factores vii ou viia |
DE602005021509D1 (de) | 2004-08-17 | 2010-07-08 | Csl Behring Gmbh | Modifizierte vitamin-k-abhängige polypeptide |
WO2006114105A2 (en) * | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
ES2553160T3 (es) | 2005-06-17 | 2015-12-04 | Novo Nordisk Health Care Ag | Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa |
EP1904528B1 (de) | 2005-07-13 | 2012-10-31 | Novo Nordisk Health Care AG | Wirtszellenprotein-knock-out-zellen zur herstellung therapeutischer proteine |
PT1907540E (pt) * | 2005-07-22 | 2013-02-04 | Bayer Healthcare Llc | Activação do factor vii em solução |
ES2515915T3 (es) | 2005-09-01 | 2014-10-30 | Novo Nordisk Health Care Ag | Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica |
WO2007031559A2 (en) | 2005-09-14 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
WO2007149406A2 (en) * | 2006-06-19 | 2007-12-27 | Nautilus Technology Llc | Modified coagulation factor ix polypeptides and use thereof for treatment |
JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
FR2910969B1 (fr) * | 2006-12-29 | 2009-02-27 | Lab Francais Du Fractionnement | Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon |
EP1952822A1 (de) * | 2007-01-26 | 2008-08-06 | Novo Nordisk A/S | Faktor-VII-Polypeptide mit erhöhter Affinität zu Thrombozyten |
JP5761782B2 (ja) | 2007-04-13 | 2015-08-12 | カタリスト・バイオサイエンシーズ・インコーポレイテッドCatalyst Biosciences, Inc. | 改変第vii因子ポリペプチド及びその使用 |
TWI538916B (zh) | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
WO2010149172A2 (en) | 2009-06-24 | 2010-12-29 | Rigshospitalet | SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. |
FR2947181B1 (fr) * | 2009-06-26 | 2012-05-04 | Lfb Biotechnologies | Composition de facteur vii |
TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
DK3165232T3 (da) * | 2012-12-24 | 2019-09-16 | Coagulant Therapeutics Corp | Faktor vii-polypeptider med kortvarig virkning |
HRP20230527T1 (hr) * | 2013-03-15 | 2023-08-04 | GLAdiator Biosciences, Inc. | Gla domene kao ciljni agensi |
CN104211802B (zh) * | 2013-05-29 | 2018-07-27 | 成都渊源生物科技有限公司 | 人凝血因子轻链蛋白及其应用 |
JP2019515904A (ja) * | 2016-04-14 | 2019-06-13 | アイコニック セラピューティクス,インコーポレイテッド | 新血管新生に関連する障害を治療するための組成物および方法 |
EP3833381B1 (de) | 2019-08-15 | 2022-08-03 | Catalyst Biosciences, Inc. | Modifizierte faktor-vii-polypeptide zur subkutanen verabreichung |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
JP2799316B2 (ja) | 1987-06-12 | 1998-09-17 | ヘキスト・マリオン・ルセル株式会社 | 雑種ヒトプロテインcおよびその遺伝子工学的製法 |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
JPH0246296A (ja) | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインc及びその製造方法 |
US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5041376A (en) * | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
US5225537A (en) * | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
HUT63459A (en) | 1990-01-26 | 1993-08-30 | Immuno Ag | Blood factors produced by recommbinant process, process for expressing them, as well as recombinant vaccine viruses used in the process |
JP3330932B2 (ja) * | 1990-01-29 | 2002-10-07 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 抗凝固剤タンパク質 |
US5583107A (en) | 1990-09-04 | 1996-12-10 | Cor Therapeutics, Inc. | Agents affecting thrombosis and hemostasis |
US5531916A (en) * | 1990-10-03 | 1996-07-02 | E. I. Du Pont De Nemours And Company | Hydrofluorocarbon cleaning compositions |
IE914102A1 (en) * | 1990-11-26 | 1992-06-03 | Genetics Inst | Expression of pace in host cells and methods of use thereof |
US5833982A (en) * | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
HU218890B (hu) | 1991-02-28 | 2000-12-28 | Novo Nordisk A/S | Véralvadást gátló módosított VII faktorok, ezeket kódoló polinukleotid molekulák, polinukleotid molekulával transzfektált emlős sejtek és a véralvadást gátló módosított VII faktorokat tartalmazó gyógyászati készítmények, valamint a készítmények ... |
US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
JPH0720127A (ja) * | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種pivkaの測定方法および測定試薬 |
PT699075E (pt) | 1993-05-21 | 2002-05-31 | Novo Nordisk As | Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas |
DE19531637A1 (de) * | 1995-08-28 | 1997-03-06 | Immuno Ag | Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung |
US5837843A (en) * | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
US5847085A (en) * | 1996-11-08 | 1998-12-08 | Oklahoma Medical Research Foundation | Modified protein C and methods of use thereof |
DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc L | Pegylationsverfahren |
AU740207B2 (en) | 1997-02-06 | 2001-11-01 | Novozymes A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
WO1999003887A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
ES2339196T3 (es) | 1997-07-18 | 2010-05-17 | Novo Nordisk Health Care Ag | Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente. |
US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6017882A (en) * | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
AT408613B (de) | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
DE69938435D1 (de) | 1998-10-30 | 2008-05-08 | Novozymes As | Niedrigallergene Proteinvarianten |
ATE365210T1 (de) | 1998-10-30 | 2007-07-15 | Novozymes As | Glykosylierte proteine mit reduzierter allergenität |
DE69939548D1 (de) | 1998-11-06 | 2008-10-23 | Novo Nordisk Healthcare Ag | Verfahren zur herstellung von faktor vii |
AU3629800A (en) | 1999-03-16 | 2000-10-04 | Children's Hospital Of Philadelphia, The | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
JP2003521930A (ja) * | 2000-02-11 | 2003-07-22 | マキシゲン・エイピーエス | 第VII因子または第VIIa因子様分子 |
US7220837B1 (en) * | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
EP1282693B1 (de) | 2000-05-03 | 2010-10-20 | Novo Nordisk Health Care AG | Varianten des menschlichen Koagulationsfaktors VII |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
WO2002022776A2 (en) | 2000-09-13 | 2002-03-21 | Novo Nordisk A/S | Human coagulation factor vii variants |
KR100882482B1 (ko) * | 2000-09-13 | 2009-02-06 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 사람 응고 인자 vii 변이체 |
EP1325113B1 (de) | 2000-10-02 | 2010-04-21 | Novo Nordisk Health Care AG | Glykoformen von faktor vii |
WO2002038162A1 (en) | 2000-11-09 | 2002-05-16 | The Scripps Research Institute | MODIFIED FACTOR VIIa |
KR20030085041A (ko) | 2001-03-22 | 2003-11-01 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 응고 인자 ⅶ 유도체 |
HUP0500060A3 (en) | 2001-09-27 | 2010-01-28 | Novo Nordisk Healthcare Ag | Human coagulation factor vii polypeptides |
ES2490590T3 (es) | 2001-11-02 | 2014-09-04 | Novo Nordisk Health Care Ag | Polipéptidos de factor VII de coagulación humana |
PL370652A1 (en) | 2001-12-21 | 2005-05-30 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
AU2003221469A1 (en) * | 2002-04-30 | 2003-11-17 | Bayer Healthcare Llc | FACTOR VII OR VIIa POLYPEPTIDE VARIANTS |
DE60336741D1 (de) | 2002-09-30 | 2011-05-26 | Bayer Healthcare Llc | FVII- ODER FVIIa-VARIANTEN MIT ERHÖHTER KOAGULATIONSWIRKUNG |
JP4847856B2 (ja) | 2003-03-20 | 2011-12-28 | バイエル ヘルスケア エルエルシー | FVIIおよびFVIIaの変種 |
US20060116324A1 (en) * | 2003-06-13 | 2006-06-01 | Novo Nordisk Healthcare A/G | Novel formulations |
PT1644504E (pt) * | 2003-06-19 | 2010-03-22 | Bayer Healthcare Llc | Variantes do domínio gla dos factores vii ou viia |
-
2004
- 2004-06-18 PT PT04738925T patent/PT1644504E/pt unknown
- 2004-06-18 CN CN2004800237774A patent/CN1839203B/zh not_active Expired - Fee Related
- 2004-06-18 ES ES04738925T patent/ES2338425T3/es active Active
- 2004-06-18 BR BRPI0411650-0A patent/BRPI0411650A/pt not_active IP Right Cessation
- 2004-06-18 PL PL04738925T patent/PL1644504T3/pl unknown
- 2004-06-18 RU RU2006101391/13A patent/RU2373282C2/ru not_active IP Right Cessation
- 2004-06-18 NZ NZ573412A patent/NZ573412A/en not_active IP Right Cessation
- 2004-06-18 SI SI200431396T patent/SI1644504T1/sl unknown
- 2004-06-18 AT AT04738925T patent/ATE458057T1/de active
- 2004-06-18 CA CA2529828A patent/CA2529828C/en not_active Expired - Fee Related
- 2004-06-18 KR KR1020057024386A patent/KR101191779B1/ko not_active IP Right Cessation
- 2004-06-18 JP JP2006515723A patent/JP4915918B2/ja not_active Expired - Fee Related
- 2004-06-18 EP EP04738925A patent/EP1644504B8/de active Active
- 2004-06-18 MX MXPA05013769A patent/MXPA05013769A/es active IP Right Grant
- 2004-06-18 NZ NZ544728A patent/NZ544728A/en unknown
- 2004-06-18 AU AU2004247799A patent/AU2004247799B2/en not_active Ceased
- 2004-06-18 DK DK04738925.9T patent/DK1644504T3/da active
- 2004-06-18 WO PCT/DK2004/000428 patent/WO2004111242A1/en active Application Filing
- 2004-06-18 DE DE602004025576T patent/DE602004025576D1/de active Active
- 2004-12-22 US US11/021,239 patent/US20050164932A1/en not_active Abandoned
-
2005
- 2005-12-05 IL IL172364A patent/IL172364A/en not_active IP Right Cessation
-
2006
- 2006-01-19 ZA ZA2006/00539A patent/ZA200600539B/en unknown
- 2006-04-21 US US11/379,664 patent/US20060252128A1/en not_active Abandoned
- 2006-06-14 US US11/424,030 patent/US7807638B2/en not_active Expired - Fee Related
- 2006-06-14 US US11/424,035 patent/US8987202B2/en not_active Expired - Fee Related
- 2006-12-21 US US11/643,535 patent/US20070117756A1/en not_active Abandoned
-
2007
- 2007-01-12 HK HK07100447.2A patent/HK1095357A1/xx not_active IP Right Cessation
-
2010
- 2010-03-02 AU AU2010200793A patent/AU2010200793B2/en not_active Ceased
- 2010-04-23 CY CY20101100374T patent/CY1109984T1/el unknown
- 2010-05-12 HR HR20100264T patent/HRP20100264T1/hr unknown
-
2011
- 2011-12-20 JP JP2011277848A patent/JP5580283B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109984T1 (el) | Παραλλαγες gla πεδιου παραγοντα vii ή viia | |
BR0009480A (pt) | Soluções de poliuretano com unidades de estrutura de alcoxissilano | |
HK1069316A1 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
MXPA04001037A (es) | Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina. | |
IL195338A (en) | An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use | |
MXPA05009682A (es) | Metodos de radiofluorinacion de vectores biologicamente activos. | |
YU72002A (sh) | Benzoilpirazoli i njihova primena u ulozi herbicida | |
UA91680C2 (ru) | Производные сульфаматов и сульфамидов для лечения эпилепсии и сопутствующих расстройств | |
IS2517B (is) | Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki | |
MXPA06003474A (es) | Agonistas de receptores de melanocortina. | |
ITMI20041550A1 (it) | Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide | |
GB0111186D0 (en) | Novel compounds | |
DE602004017871D1 (de) | Zubereitungen zur behandlung von arthritischen erscheinungen | |
ES2177316T3 (es) | Anticuerpos humanos antifacotores ix/ixa. | |
BR0213072A (pt) | Sabonete em barra | |
DE60228878D1 (de) | Proteine mit il-6 inhibitorischer wirkung | |
MXPA04005079A (es) | Variantes del dominio c2 del factor viii. | |
IL162600A0 (en) | Cc-chemokine mutants as cc-chemokine antagonists | |
MXPA04001986A (es) | Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad. | |
ATE526056T1 (de) | Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes | |
RS20060023A (en) | Use of soluble cd164 in inflammatory and/or autoimmune disorders | |
DE50207110D1 (de) | Kombinationspräparat zur behandlung des diabetes mellitus | |
BRPI0409586A (pt) | ácidos hidroxámicos úteis no tratamento de distúrbios hiperproliferativos | |
EA200600956A1 (ru) | Молекулы-антагонисты цитокинов | |
IN2009CN00831A (de) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1644504 Country of ref document: EP |